



State of New Jersey
DEPARTMENT OF HEALTH
PO BOX 360
TRENTON, N.J. 08625-0360
www.nj.gov/health

PHILIP D. MURPHY
Governor

SHEILA Y. OLIVER
Lt. Governor

JUDITH M. PERSICILLI, RN., BSN, MA
Commissioner

EXECUTIVE DIRECTIVE NO: 19-004(D)

Addition of Suboxone ® to the Advanced Life Support Optional Formulary

WHEREAS, pursuant to N.J.A.C. 8.41-9.11(b)(1), former Commissioner Shereef M. Elnahal issued Executive Directive 19-004, which authorized the addition of Suboxone®, or the generic equivalent, to the list of medications and therapeutic agents in the optional formulary for mobile intensive care paramedics to treat the symptoms of an acute opioid withdrawal, subsequent to the administration of naloxone; and

WHEREAS, Executive Directive 19-004 was set to expire on December 24, 2019; and

WHEREAS, Executive Directive 19-004 was extended by Acting Commissioner Judith Persichilli, R.N., B.S.N., M.A., through June 24, 2020 via Executive Directive 19-004(A); and

WHEREAS, Executive Directive 19-004(A) was extended by Commissioner Persichilli through December 24, 2020 via Executive Directive 19-004(B); and

WHEREAS, Executive Directive 19-004(B) was extended by Commissioner Persichilli through June 24, 2021 via Executive Directive 19-004(C); and

WHEREAS, under N.J.A.C. 8.41-9.11(b)(1), Executive Directive 19-004(C) may be extended for a period of six months if the public health concerns addressed in the Executive Directive continue past its expiration date and the Chairman of the Mobile Intensive Care Unit (MICU) Advisory Council requests such an extension;

WHEREAS, on May 4, 2021, the Chairman of the MICU Advisory Council requested that Executive Directive 19-004(C) be extended for an additional six months;

WHEREAS, the Department of Health acknowledges that New Jersey is still experiencing a public health crisis due to opioid use disorder and it remains committed to garnering all possible resources to combat the opioid crisis plaguing our great State;

WHEREAS, data surrounding the administration of Suboxone by paramedics to patients following the emergent administration of naloxone continues to show promising signs that it is an effective tool in the fight against opioid use disorders;

WHEREAS, Department staff reviewed the MICU Advisory Council's submission as well as the Suboxone data and recommended the granting of the MICU Advisory Council's request.

NOW, THEREFORE, I, Judith Persichilli, Commissioner, New Jersey Department of Health, by virtue of the authority vested in me hereby:


EXTEND Executive Directive 19-004(C) for a period of six months.

BE IT FURTHER ORDERED THAT

1. **ALL** of the conditions and requirements regarding the use and administration of Suboxone that are set forth in Executive Directive 19-004, Executive Directive 19-004(A), Executive Directive 19-004(B) and Executive Directive 19-004(C) remain in full force and effect.
2. **THIS** Executive Directive shall expire on December 24, 2021, unless further extended by the Department under N.J.A.C. 8.41-9.11(b)(1).



Judith M. Persichilli, R.N., B.S.N., M.A.
Commissioner



Dated